Editorials

All That Glitters Is Not Gold — Standardizing Diagnosis in Rheumatoid Arthritis Studies .......................... 1223
K.P. Liao, V. Bykerk 

Who’s Holding up the Queue? Delay in Treatment of Rheumatoid Arthritis .......................... 1225
J.E. Homik 

Rehabilitation for Ankylosing Spondylitis in the Era of Biologics: Any Room Left for This Treatment? 1228
E. Lubrano, S. D’Angelo, A. Spadaro, C. Palazzi, I. Olivieri 

Should Clinicians Start Measuring Flow Mediated Dilation Response in Patients with Systemic Lupus Erythematosus? 1231
C.S. Lau 

Review

Challenges in Diagnosing Latent TB Infection in Patients Treated with TNF Antagonists 1234
E.C. Keystone, K.A. Papp, W. Wobeser 

Articles

Lymphotoxin-α 252 A>G Polymorphism: A Link Between Disease Susceptibility and Dyslipidemia in RA? 1244

Diagnostic Accuracy of ACR/EULAR 2010 Criteria for RA in a 2-Year Cohort 1250
S. Varache, D. Cornec, J. Morvan, et al 

Incidence and Risk Factors for Serious Infection in Patients with RA Treated with TNF Inhibitors: A Report from the Registry of Japanese RA Patients for Longterm Safety 1258
Y. Komano, M. Tanaka, T. Nanki, et al, for the REAL Study Group 

A Comparison Between IgG- and IgA-class Antibodies to CCP and to Modified Citrullinated Vimentin in Early RA and Very Early Arthritis 1265
A. Svärd, A. Kastbom, M.K. Söderlin, Å. Reckner-Olsson, T. Skogh 

Persistence with Anti-TNF Therapies in Patients with RA: Observations from the RADIUS Registry 1273
J.A. Markenson, A. Gibofsky, W.R. Palmer, et al 

Time to Treatment for New Patients with RA in a Major Metropolitan City 1282
S. Jamal, S.M.H. Alibhai, E.M. Badley, C. Bombardier 

Prognostic Indicators of Hospitalized Patients with SLE: A Large Retrospective Multicenter Study in China 1289
X. Feng, Y. Zou, W. Pan, et al 

Endothelium-dependent But Not Endothelium-independent Flow-mediated Dilation Is Significantly Reduced in Patients with SLE without Vascular Events: A Metaanalysis and Metaregression 1296
A. Mak, Y. Liu, R.C-M Ho 

Longterm Followup After Tapering MMF During Maintenance Treatment for Proliferative Lupus Nephritis 1304
K. Laskari, A.G. Tzioufas, A. Antoniou, H.M. Moutsopoulos 

Quantitative Data for Care of Patients with SLE in Usual Clinical Settings: A Patient Multidimensional HAQ and Physician Estimate of Noninflammatory Symptoms 1309
A.D. Askarane, I. Castrejón, T. Pincus 

Late-age Onset SSc 1317
R.L. Manno, F.M. Wigley, A.C. Gelber, L.K. Hummers 

Expert Agreement on EULAR/EUSTAR Recommendations for the Management of SSc 1326
K.M. Walker, J. Pope, on behalf of the Scleroderma Clinical Trials Consortium and the Canadian Scleroderma Research Group 

Malignancies in Italian Patients with SSC Positive for Anti-RNA Polymerase III Antibodies 1329

Rehabilitation Treatment in Patients with AS Stabilized with TNF Inhibitor Therapy, A Randomized Controlled Trial 1335
S. Masiero, L. Bonaldo, M. Pigatto, A. Lo Nigro, R. Ramonda, L. Punzi 

The SPARCC Registry for SpA 1343

Resolution of Inflammation Following Treatment of AS Associated with New Bone Formation 1349

Effectiveness and Safety of Etanercept in Patients with PsA in a Canadian Clinical Practice Setting: The REPARe Trial 1355

High Prevalence of Subclinical Left Ventricular Dysfunction in Patients with PsA 1363

Prevalence of Thyroid Autoimmunity in Patients with SpA 1371

Candidate Genes in Patients with Autoinflammatory Syndrome Resembling TNF Receptor-associated Periodic Syndrome Without Mutations in the TNFRSF1A Gene 1378
S. Borghini, M. Fiore, M. Di Duca, et al 

Notes

Free online via JRheum Full Release option